Trump’s push to freeze funding leaves researchers anxious about delayed scientific breakthroughs
Institutions, biotech startups and life sciences companies are all conducting research and clinical trials that depend on federal grants and contracts. The lingering threat that the Trump administration could still freeze the funding continues to disrupt research.
Marc Cummings, president and CEO of Life Science Washington, said the initial threat of a pause in funding had researchers scrambling for contingency plans. “Research is a long-term endeavor and funding is often tied to specific projects and individual researchers,” Cummings said by email. “You can’t pay them one day and not the next. Likewise, many companies and research institutes build research teams and staff project based on known funding cycles.”
Despite the uncertainty, the region’s resilience and interconnected life science community position it to continue driving innovation in the face of challenges.